F.O.S. Christopher Mason Interview

🚀 The Future of Space video podcast is a candid and informal conversation, between myself and leaders, investors, innovators, educators, celebrities, movers, and shakers that are shaping the future of humankind into outer space. Like how two friends would chat and philosophe. With just one thing missing, a glass of wine! 🚀 Today's guest is Christopher Mason. He is an Associate Professor at Weill Cornell Medicine and co-founder of Onegevity Health, a platform designed to empower individuals to maintain optimal health by democratizing access to actionable information from leading-edge biomedical research. Mason has been a pioneer in next-generation sequencing (NGS) diagnostics, multi-omic approaches to modeling disease, and new biochemical and genomic methods. Christopher Mason Website https://www.masonlab.net Linkedin https://www.linkedin.com/in/christopher-mason-4972a119/ Twitter https://twitter.com/mason_lab Weill Cornell University Website https://weill.cornell.edu Onegevity Website https://www.onegevity.com Biotia Website https://www.biotia.io Tempus Labs Website https://www.tempus.com 00:00 Introduction 00:45 3 words to describe Space? INSPIRING. NECESSARY. FUN 01:20 What is the human story of going to Space? 03:10 A quantum leap in evolution 05:30 The success of the human species and Awareness 08:20 Awareness of being the best and worst of Nature 10:45 Homo Deus 12:35 We will live longer but maybe not be bigger 15:05 Our presence in space will be biotech 17:00 Engineering nature for our survival 19:50 We are not going to re-invent the wheel 21:25 The impossible becoming possible 24:30 Nurturing compassion and humility in an era of customization 26:40 Unintended consequences 29:30 Is utopia possible? 31:10 Is immortality possible? 33:20 Jujitsu or street fighting? 36:15 500 years, the book 39:10 A lactose tolerant future 42:00 Titan, the movie and enjoying movies 43:45 Where to find the book 500 Years 44:20 What is next? 46:45 Conclusion

There are no comments yet.

Please log in to write the first comment.